284 related articles for article (PubMed ID: 34659566)
1. Endometriosis-associated Ovarian Clear Cell Carcinoma: A Special Entity?
Sun Y; Liu G
J Cancer; 2021; 12(22):6773-6786. PubMed ID: 34659566
[TBL] [Abstract][Full Text] [Related]
2. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
Oda K; Hamanishi J; Matsuo K; Hasegawa K
Gynecol Oncol; 2018 Nov; 151(2):381-389. PubMed ID: 30217369
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte nuclear factor-1β (HNF-1β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma.
Okamoto T; Mandai M; Matsumura N; Yamaguchi K; Kondoh H; Amano Y; Baba T; Hamanishi J; Abiko K; Kosaka K; Murphy SK; Mori S; Konishi I
Mol Carcinog; 2015 Jan; 54(1):35-49. PubMed ID: 24105991
[TBL] [Abstract][Full Text] [Related]
4. Molecular changes in endometriosis-associated ovarian clear cell carcinoma.
Worley MJ; Liu S; Hua Y; Kwok JS; Samuel A; Hou L; Shoni M; Lu S; Sandberg EM; Keryan A; Wu D; Ng SK; Kuo WP; Parra-Herran CE; Tsui SK; Welch W; Crum C; Berkowitz RS; Ng SW
Eur J Cancer; 2015 Sep; 51(13):1831-42. PubMed ID: 26059197
[TBL] [Abstract][Full Text] [Related]
5. Novel insights on the malignant transformation of endometriosis into ovarian carcinoma.
Gadducci A; Lanfredini N; Tana R
Gynecol Endocrinol; 2014 Sep; 30(9):612-7. PubMed ID: 24905724
[TBL] [Abstract][Full Text] [Related]
6. Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma.
Wong OGW; Li J; Cheung ANY
Front Oncol; 2021; 11():666815. PubMed ID: 34737943
[TBL] [Abstract][Full Text] [Related]
7. Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.
Wang Q; Wang L; L Y; Ding X; Liu A
J BUON; 2017; 22(5):1314-1321. PubMed ID: 29135119
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic Significance of HNF-1β, AIRD1A, and PIK3CA Expression in Ovarian Clear Cell Carcinoma: A Tissue Microarray Study of 130 Cases.
Ye S; Yang J; You Y; Cao D; Huang H; Wu M; Chen J; Lang J; Shen K
Medicine (Baltimore); 2016 Mar; 95(9):e3003. PubMed ID: 26945423
[TBL] [Abstract][Full Text] [Related]
9. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes.
Yamaguchi K; Mandai M; Oura T; Matsumura N; Hamanishi J; Baba T; Matsui S; Murphy SK; Konishi I
Oncogene; 2010 Mar; 29(12):1741-52. PubMed ID: 20062075
[TBL] [Abstract][Full Text] [Related]
10. Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?
Sahin H; Sari ME; Cuylan ZF; Haberal AN; Sirvan L; Coban G; Yalcin I; Güngör T; Celik H; Meydanli MM; Ayhan A
Arch Gynecol Obstet; 2018 Apr; 297(4):1005-1013. PubMed ID: 29383437
[TBL] [Abstract][Full Text] [Related]
11. Expression of protease-activated receptor-2 (PAR-2) is related to advanced clinical stage and adverse prognosis in ovarian clear cell carcinoma.
Aman M; Ohishi Y; Imamura H; Shinozaki T; Yasutake N; Kato K; Oda Y
Hum Pathol; 2017 Jun; 64():156-163. PubMed ID: 28438620
[TBL] [Abstract][Full Text] [Related]
12. Current and future strategies for treatment of ovarian clear cell carcinoma.
Ogasawara A; Sato S; Hasegawa K
J Obstet Gynaecol Res; 2020 Sep; 46(9):1678-1689. PubMed ID: 32578333
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Strategies Focused on Cancer-Associated Hypercoagulation for Ovarian Clear Cell Carcinoma.
Tamura R; Yoshihara K; Enomoto T
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565252
[TBL] [Abstract][Full Text] [Related]
14. Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.
Zhu C; Xu Z; Zhang T; Qian L; Xiao W; Wei H; Jin T; Zhou Y
J Cancer; 2021; 12(8):2295-2316. PubMed ID: 33758607
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma.
Kawabata A; Yanaihara N; Nagata C; Saito M; Noguchi D; Takenaka M; Iida Y; Takano H; Yamada K; Iwamoto M; Kiyokawa T; Okamoto A
Gynecol Oncol; 2017 Sep; 146(3):609-614. PubMed ID: 28673661
[TBL] [Abstract][Full Text] [Related]
16. Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.
Takahashi K; Takenaka M; Kawabata A; Yanaihara N; Okamoto A
Int J Clin Oncol; 2020 Mar; 25(3):425-431. PubMed ID: 31989349
[TBL] [Abstract][Full Text] [Related]
17. CRISPR/Cas9 Screening for Identification of Genes Required for the Growth of Ovarian Clear Cell Carcinoma Cells.
Kawabata A; Hayashi T; Akasu-Nagayoshi Y; Yamada A; Shimizu N; Yokota N; Nakato R; Shirahige K; Okamoto A; Akiyama T
Curr Issues Mol Biol; 2022 Apr; 44(4):1587-1596. PubMed ID: 35723366
[TBL] [Abstract][Full Text] [Related]
18. Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma.
Xiao W; Awadallah A; Xin W
Int J Clin Exp Pathol; 2012; 5(7):642-50. PubMed ID: 22977660
[TBL] [Abstract][Full Text] [Related]
19. Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute.
Zhao T; Shao Y; Liu Y; Wang X; Guan L; Lu Y
J Ovarian Res; 2018 Jun; 11(1):53. PubMed ID: 29941051
[TBL] [Abstract][Full Text] [Related]
20. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.
Samartzis EP; Noske A; Dedes KJ; Fink D; Imesch P
Int J Mol Sci; 2013 Sep; 14(9):18824-49. PubMed ID: 24036443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]